Congenital adiponectin deficiency mitigates high-fat-diet-induced obesity in gonadally intact male and female, but not in ovariectomized mice

Christian A. Unger1, Ahmed K. Aladhami1,2, Marion C. Hope III1, Sahar Pourhoseini3, Mitzi Nagarkatti1, Owen P. McGuinness3, E. Angela Murphy1, Kandy T. Velázquez1 & Reilly T. Enos1*

Epidemiological literature indicates that women are less susceptible to type II diabetes (T2D) than males. The general consensus is that estrogen is protective, whereas its deficiency in post-menopause is associated with adiposity and impaired insulin sensitivity. However, epidemiological data suggests that males are more prone to developing T2D, and at a lower BMI, compared to females during post-menopausal years; suggesting that another factor, other than estrogen, protects females. We proposed to determine if adiponectin (APN) serves as this protective factor. An initial experiment was performed in which gonadally intact male and female mice were fed either a purified low-fat diet (LFD) or high-fat diet (HFD) (40% kcals from fat) for 16 weeks. An additional group of HFD ovariectomy (OVX) mice were included to assess estrogen deficiency’s impact on obesity. Body composition, adipose tissue inflammation, ectopic lipid accumulation as well as glucose metabolism and insulin resistance were assessed. In corroboration with previous data, estrogen deficiency (OVX) exacerbated HFD-induced obesity in female mice. However, despite a higher body fat percentage and a similar degree of hepatic and skeletal muscle lipid accumulation, female OVX HFD-fed mice exhibited enhanced insulin sensitivity relative to HFD-fed males. Therefore, a subsequent HFD experiment was performed utilizing male and female (both gonadally intact and OVX) APN deficient mice (APN−/−) and wildtype littermates to determine if APN is the factor which protects OVX females from the similar degree of metabolic dysfunction as males in the setting of obesity. Indirect calorimetry was used to determine observed phenotype differences. APN deficiency limited adiposity and mitigated HFD-induced insulin resistance and adipose tissue inflammation in gonadally intact male and female, but not in OVX mice. Using indirect calorimetry, we uncovered that slight, but non-statistically significant differences in food intake and energy expenditure leading to a net difference in energy balance likely explain the reduced body weight exhibited by male APN-deficient mice. In conclusion, congenital APN deficiency is protective against obesity development in gonadally intact mice, however, in the setting of estrogen deficiency (OVX) this is not true. These findings suggest that gonadal status dictates the protective effects of congenital APN deficiency in the setting of HFD-induced obesity.

Abbreviations
APN  Adiponectin
HFD  High-fat diet
LFD  Low-fat diet
OVX  Ovariectomized

1Department of Pathology, Microbiology, and Immunology, University of South Carolina-School of Medicine, 6439 Garners Ferry Rd, Columbia, SC 29209, USA. 2Nursing College, University of Baghdad, Baghdad, Iraq. 3Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. *email: enosr@email.sc.edu
Epidemiological literature indicates that women are less susceptible to type II diabetes (T2D) than males. This is largely regulated by sex hormones—estrogen, in particular. The general consensus is that estrogen is protective, whereas its deficiency in post-menopausal women is associated with adiposity and impaired insulin sensitivity1-3. However, epidemiological data suggests that males are more prone to developing T2D, and at a lower BMI, as compared to females during mid-life (post-menopausal, estrogen-deficient years); suggesting that another factor, other than estrogen, protects females4-6. Human data suggests that adiponectin (APN) increases during estrogen deficiency and may serve as this protective factor7; but this has not been mechanistically examined.

APN is a well-established adipokine whose role as a beneficial or detrimental factor in a variety of diseases remains controversial8-11. Although the general consensus is that APN has a beneficial effect on metabolic processes, contrary publications suggest that APN deficiency actually reduces body fat%, protects against NAFLD development, and enhances skeletal muscle beta oxidation12-14. Furthermore, a limitation of previous investigations is that the primary focus in these experiments has been on male mice. This is surprising given that both in vitro and epidemiological investigations suggest estrogen status plays a significant role in impacting APN production. For example, experiments performed in adipocytes show that estrogen reduces intra- and extra-cellular APN15. In humans, there are strong negative associations of serum APN with estrogen and the stage of menopause16-20. Additionally, estrogen replacement therapy in post-menopausal females reduces plasma APN levels21. To date the in vivo interaction of APN and estrogen status in the setting of diet-induced obesity has not been investigated.

Here we show that ovariectomized female mice on a high-fat diet (HFD) present a similar degree of visceral adiposity, a greater body fat percentage, and an analogous degree of hepatic steatosis as HFD-fed male mice, yet present a significantly superior insulin sensitive phenotype. In this investigation, we probe to answer the question whether APN is a key molecule that regulates this enhanced metabolic phenotype in an estrogen-deficient state relative to similarly obese males.

Material and methods

Animals. For experiments in which APN KO were not utilized, wildtype (WT) mice on a C57BL/6J background were purchased from Jackson Laboratories (Bar Harbor, ME). For all other experiments utilizing APN KO mice, APN−/− mice on a C57BL/6J background (a kind gift from Dr. Philipp Scherer, UT-Southwestern) were bred in order to produce APN KO and WT littermate controls. Mice were genotyped utilizing the following primers: ApnWf: 5′-TTG GAC CCC TGA ACT TGC TTC ACA CC-3′, ApnWTr: 5′-TCCTGAGTCTCAATCCCA GCACCAC-3′, ApnKOr: 5′-GGATCGGCTGGGTCTATGGCTTC-3′ with the following PCR conditions: (95 °C, 5 min)—[(95 °C, 15 s)—(62 °C, 30 s)—(72 °C, 30 s)] X 35—(72 °C, 3 min). All ovariectomy surgeries were performed at ≈ 10 weeks of age when female mice were sexually mature. Mice were given one week recovery before the initiation of dietary treatment. The sample size for each experimental group is presented in the legend of each figure. All methods were in accordance with the American Association for Laboratory Animal Science, and the Institutional Animal Care and Usage Committee of the University of South Carolina approved all experiments. The authors complied with the ARRIVE guidelines.

Diet. At 11 weeks of age, mice were assigned to receive either a purified low-fat diet (LFD) or a custom high-fat diet for a duration of 16 weeks. We have found this length of feeding to be sufficient to induce an obese phenotype characterized by impaired glucose metabolism, hyperinsulinemia, and adipose tissue inflammation18-20. The LFD utilized in this experiment was the open-source, purified AIN-76A diet (3.77 kcal/g) comprised of 69%, 12%, and 19% of total kcals from carbohydrate, fat, and protein, respectively. The HFD (4.57 kcal/g) was a purified diet comprised of 47%, 40%, and 13% of total calories from carbohydrate, fat, and protein, respectively, with saturated fat making up 12% of total calories in order to mimic the standard American diet (BioServ, Frenchtown, NJ). Details and previous use of this diet are provided elsewhere18-20. Longitudinal body composition measurements were assessed after ≈ 12 and ≈ 16 weeks of dietary treatment and fasting blood glucose and insulin levels were assessed after ≈ 12 and 16 weeks of dietary treatment. After a 5-h fast, blood samples were collected from the tip of the tail. A glucometer (Bayer Contour, Mishawaka, IN) was used to determine blood glucose concentrations in whole blood. Collected blood was centrifuged at 4000 rpm for 10 min at 4 °C. Plasma insulin concentrations were analyzed according to the manufacturer's instructions using a mouse insulin ELISA kit (Mercodia, Winston Salem, NC). Glucose and insulin tolerances tests (GTTs and ITTs, respectively) were performed after ≈ 12 and ≈ 16 weeks of dietary treatment.

Body weight and body composition. Body weight was monitored on a weekly basis throughout the study. Body composition was assessed after ≈ 12 and ≈ 16 weeks of diet in order to use lean mass as the basis for the dose of glucose and insulin administration for glucose and insulin tolerance tests, respectively. The intention for assessing metabolic outcomes at two different time points was to determine if the length of dietary feeding differentially impacted metabolic outcomes between groups. For this procedure, mice were briefly anesthetized via isoflurane inhalation, and lean mass, fat mass, and percent body fat were assessed by dual-energy X-ray absorptiometry (Lunar PIXIImus).

Metabolism. Fasting blood glucose and insulin levels were assessed after ≈ 12 and 16 weeks of dietary treatment. After a 5-h fast, blood samples were collected from the tip of the tail. A glucometer (Bayer Contour, Mishawaka, IN) was used to determine blood glucose concentrations in whole blood. Collected blood was centrifuged at 4000 rpm for 10 min at 4 °C. Plasma insulin concentrations were analyzed according to the manufacturer's instructions using a mouse insulin ELISA kit (Mercodia, Winston Salem, NC). Glucose and insulin tolerances tests (GTTs and ITTs, respectively) were performed after ≈ 12 and ≈ 16 weeks of dietary treatment.
GTTs and ITTs were performed a week apart (e.g. after 11.5 and 12.5 weeks and after 15.5 and 16.5 weeks of dietary treatment) to allow for animal recovery between metabolic tests. For these procedures, mice were fasted for 5 h, and glucose or insulin was administered intraperitoneally at 2 g/kg lean mass or 0.75 U/kg lean mass, respectively. A glucometer (Bayer Contour) was used to measure blood glucose concentrations (tail sampling) intermittently over a 2-h period (0, 15, 30, 60, 90, and 120 min) for GTTs and intermittently over a 45-min period (0, 15, 30, and 45 min) for ITTs. Area of the Curve (AUC) after subtracting baseline blood glucose levels was calculated using the trapezoidal rule based off of the insights by Virtue and Vidal-Puig. Blood was collected from the tip of the tail during the GTT (0, 15, 30, 60, and 120 min) in order to assess the insulin response to the GTT for a subset of mice from each group. Fasting serum was collected (using non-heparinized capillary tubes) for free fatty acid (FFA) analysis using a commercially available kit (Wako Diagnostics, Richmond, VA). Fasting plasma was collected for circulating triglyceride levels using a commercially available kit (Infinity Triglyceride Reagent, Thermo Fisher Scientific, Waltham, MA). In order to assess tissue-specific insulin signaling, a sub-set of mice were fasted for 5 h and were subsequently administered 0.75 U/kg lean mass of insulin or PBS. At 7 min after insulin administration, the mice were euthanized (cervical dislocation) and the gastrocnemius was quickly harvested and snap-frozen in liquid nitrogen in order to assess insulin signaling in the gastrocnemius skeletal muscle.

**Tissue collection.** After 16 weeks of dietary treatment, mice were euthanized via isoflurane inhalation for tissue collection. Epididymal, mesenteric, and perirenal fat pads, as well as the liver, and skeletal muscle (gastrocnemius) were removed, weighed, and immediately snap-frozen in liquid nitrogen and stored at −80 °C for tissue collection. Formalin-fixed tissues were embedded in paraffin blocks and sectioned (Instrumentation Resource Facility at the University of South Carolina). Livers were stained with hematoxylin and eosin (Biocare, Pacheco, CA). Representative images were taken at 10x (Nikon E600).

**Hepatic and skeletal muscle lipid content.** Hepatic and skeletal muscle triglyceride assessments were performed as previously described. For total hepatic lipid assessment, lipids were isolated from the liver utilizing a modified Folch extraction method and quantified gravimetrically, as previously described.

**Liver histology.** Formalin-fixed tissues were embedded in paraffin blocks and sectioned (Instrumentation Resource Facility at the University of South Carolina). Livers were stained with hematoxylin and eosin (Biocare, Pacheco, CA). Representative images were taken at 10x (Nikon E600).

**Plasma leptin and high-molecular weight (HMW) APN assessment.** Plasma leptin and HMW APN were determined using commercially-available ELISA kits (R&D Systems, Minneapolis, MN and ALPCO, Salem, New Hampshire for leptin and HMW APN, respectively).

**Quantitative real-time PCR.** An E.Z.N.A. Total RNA Kit (Omega Bio-Tek, Norcross, GA) was used to isolate RNA from gonadal adipose tissue. Taqman reverse transcription reagents and probe assays (Applied Biosystems, Waltham, MA) were used to reverse transcribe and analyze expression of the following genes in gonadal adipose tissue: F4/80, CD11c, CD206, MCP-1, TNFα, IL-10, CXCL14, TLR2, PPARγ, and PGC1-α. Potential reference genes (HPRT, 18s, GAPDH, β-Actin, HMBS, TBP, H2AFV, and B2M) were analyzed for stability using Qbase+ software (Biogazelle, Ghent, Belgium). The optimal number of reference genes was determined by Qbase + (HMBS & H2afv), and the geometric mean of these genes was used as the normalization factor for each analysis. Gene expression was quantified using the ΔΔCT method and Qbase + software.

**Western blotting.** Briefly, gonadal fat and skeletal muscle were homogenized in Mueller Buffer containing a protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO). Total protein concentrations were determined by the Bradford method. Equal amounts of crude protein homogenates were fractioned on hand-casted 12% SDS–polyacrylamide gel and electrophoretically transferred to a PVDF membrane using a Genie Blotter (IDEA Scientific, Minneapolis, MN). 0.5 μL of plasma was used to verify the absence of circulating adiponectin in APN KO mice. Membranes were stained with a Ponceau S solution in order to verify equal protein loading and transfer efficiency. Subsequently, membranes were blocked for 1 h in 5% milk in Tris-buffered saline, 0.1% Tween-20 (TBST). The AKT, p-AKT, and p-JNK antibodies (Cell Signaling, Danvers, MA) as well as the adiponectin antibody (Biovendor, Karasek, Czech Republic) were diluted 1:1000 in a 5% milk-TBST overnight at 4°C and JNK (Cell Signaling, Danvers, MA for 2 h at room temperature). An anti-rabbit (Cell Signaling, Danvers, MA) IgG hors eradish peroxidase conjugated secondary antibody was diluted 1:2000 in 5% milk-TBST and incubated for 1 h at room temperature. An enhanced chemiluminescent substrate for detection of horseradish peroxidase (Thermo Scientific, Watham, MA) was used to visualize the antibody-antigen interaction. Autoradiography films were scanned and blots were quantified using scientific imaging software (Image J). After completion of the western blot, all membranes were stained with Amido black or ponceau and the densitometry of each lane was calculated using Quantity One Software (Biorad, Hercules, CA) allowing for total protein normalization. This method of normalization has been shown to be more accurate than typically used loading controls. Complete western blots are presented in Supplementary Fig. 8. Please note as western blots were captured with autoradiography film, the films were pre-cut or cut after film developing prior to scanning for imaging.

**Food intake assessment.** In experiments in which food individual food intake was assessed, mice were singly-housed for 16 weeks. Individual food intake for each mouse was assessed on a weekly basis.
**Indirect calorimetry and behavioral phenotyping.** Male APN KO and WT littermate controls (n = 7–8/group) were fed a HFD for 6 weeks, underwent body composition analysis (DEXA), and were placed into a 16-cage Promethion multichannel continuous measurement indirect calorimetry system (Sable System International, Las Vegas, NV, USA) on a 12-h light and 12-h dark cycle for a 11-day period. After a 1-day acclimation period, food intake, water consumption, body mass, total activity, total energy expenditure, resting energy expenditure, oxygen consumption, carbon dioxide production, respiratory quotient, and animal locomotion (all meters) were determined and analyzed over a ten-day period. All data (besides RER and all meters = two-tailed student's T-test) were analyzed using an ANCOVA with lean mass as a covariate utilizing the MMPC Statistical Analysis Page (https://www.mmopc.org/shared/regression.aspx). CaR was used to assess energy balance and for the creation of the net energy balance and RER figures over time.

**Statistical analysis.** Data were analyzed using commercially available statistical software: Prism 9 (GraphPad Software, La Jolla, CA, www.graphpad.com). A one-way ANOVA followed by a Newman-Keuls post hoc test was used for all experiments utilizing WT mice only. A two-way ANOVA (genotype vs. sex) followed by a Newman-Keuls post-hoc analysis was used to assess differences between Female WT, Female APN KO, Male WT, and Male APN KO mice as well as a two-way ANOVA (genotype vs. gonadal status) followed by a Newman-Keuls post-hoc analysis in order to determine differences between Male WT, Male APN KO, OVX WT, and OVX APN KO. A two-tailed student's t-test was used when only two groups were compared. Any statistical test that did not pass the equal-variance test (Bartlett's test for equal variances) was log-transformed and then reanalyzed. Data are presented as means ± SE, and the level of significance was set at P < 0.05.

**Results**

Despite similar increases in adiposity as a result of HFD consumption, OVX mice exhibit reduced adipose tissue inflammation compared to HFD-fed males. Male and female mice were fed a LFD or HFD for 16 weeks (n = 10/group). An additional group of HFD OVX mice (n = 7) were included in the study design in order to assess the impact of estrogen deficiency on the development of the obese phenotype. Body weight gain, as well as visceral and total fat accumulation, and plasma leptin were greatest in the male and OVX HFD mice, followed by the female HFD, male LFD, and finally female LFD mice (Fig. 1A–E) (P < 0.05). However, because male mice displayed greater lean mass than female mice, the body fat% was greatest in the OVX HFD mice compared to all other groups (Fig. 1D) (P < 0.05). In order to determine the impact that weight gain had on adipose inflammation, we performed qRT-PCR in the gonadal adipose tissue for all experimental groups (Fig. 2A). Within males, HFD feeding increased the gene expression of all inflammatory mediators: MCP-1, TNF-α, TLR2, CXCL14, IL-10 and macrophage markers measured: F4/80 (general macrophage marker), CD11c (M1 macrophage marker), and CD206 (M2 macrophage marker) (P < 0.05). As it has already been established that a sexual dichotomy exists with respect to the inflammatory response to HFD consumption between males and females, it was not surprising to find that HFD-fed females only displayed increased gonadal MCP-1, TNF-α, and CD11c gene expression relative to LFD-fed mice (P < 0.05), but not TLR2, CXCL14, IL-10, F4/80, and CD206 mRNA content. Given that estrogen is known to play an important role in regulating inflammatory and metabolic processes, it was anticipated and confirmed that estrogen deficiency in a HFD setting increased the gene expression of all inflammatory markers measured relative to intact female HFD mice (P < 0.05). Nonetheless, it was unexpected to find that despite the similar levels of gonadal fat, male HFD mice displayed significant increases in gonadal adipose tissue inflammation at the mRNA level (MCP-1, TNF-α, TLR2, F4/80, CD11c, and CD206), and at the protein level as evidenced by increased JNK phosphorylation protein content (Fig. 2B) (P < 0.05).

Despite similar increases in adiposity and ectopic lipid accumulation as a result of HFD consumption, OVX mice exhibit enhanced insulin sensitivity relative to HFD-fed males. In our initial preliminary study, we assessed fasting blood glucose incrementally throughout the experimental protocol as well as fasting insulin after 16 weeks of diet consumption (Supplementary Fig. 1). All groups displayed significantly higher fasting blood glucose and insulin levels compared to female LFD mice (P < 0.05). However, the male HFD mice displayed a 1.25× and 3.4× increase in fasting blood glucose AUC and insulin levels, respectively, relative to OVX HFD mouse (Supplementary Fig. 1) (P < 0.05). In order to perform more advanced metabolic tests to corroborate our initial findings, a second study was performed (n = 10/group) in which metabolic outcomes were assessed after 12 and 16 weeks of dietary feeding. After 12 weeks of HFD consumption, our initial results were corroborated—despite presenting a lower body fat% (Supplementary Fig. 2A), the male HFD mice displayed significantly elevated fasting insulin and glucose levels compared to OVX HFD mouse (Supplementary Fig. 2B, C) (P < 0.05). However, although we did not see a difference in the AUC for the GTT between the OVX and male HFD mice, the OVX mice did display lower fasting blood glucose levels 90 and 120 min into the GTT. Additionally, the OVX HFD mice were significantly more insulin sensitive than the male HFD mice as evidenced by an ITT (Supplementary Fig. 2C) (P < 0.05). After 16 weeks of diet, GTTs and ITTs were performed yet again (Fig. 3). Male HFD mice continued to display elevated fasting insulin levels compared to OVX HFD mice (Fig. 3A) (P < 0.05). However, no difference was found in the AUC of the GTT between the male HFD and OVX HFD mice, nor did the OVX HFD mice display lower glucose levels at 90 and 120 min into the GTT after 16 weeks of feeding as was previously seen after 12 weeks of feeding (Fig. 3B). Interestingly, however, the OVX HFD mice displayed significantly lower circulating insulin over the course of the GTT, suggesting their enhanced insulin sensitivity relative to the male HFD mice (Fig. 3D) (P < 0.05). Additionally, we examined skeletal muscle...
AKT activation after an insulin bolus and found increased AKT activation in the skeletal muscle of OVX HFD mice relative to male HFD mice (Fig. 3E) (P < 0.05). In order to determine if ectopic lipid accumulation may be responsible for the differences in insulin sensitivity between the male and OVX HFD mice we examined hepatic and skeletal muscle triglyceride accumulation (Supplementary Fig. 3A-B). No difference was found in triglyceride accumulation in these two metabolic tissues between the OVX HFD and male HFD mice.

Circulating high-molecular weight (HMW) adiponectin (APN) is increased in OVX HFD mice. Our data suggest that, despite similar levels of visceral adiposity and ectopic lipid accumulation, estrogen-deficient OVX mice are still protected against the same degree of adipose tissue inflammation and metabolic dysfunction exhibited by male HFD mice. Our goal was to determine the potential mediator(s) of these effects. Subsequently, we performed an ELISA to examine circulating HMW APN as the HMW form of APN has been shown to possess insulin sensitizing properties, and to be elevated in females relative to males.35 Taking this into consideration, it was not surprising that OVX HFD mice displayed the highest levels of circulating HMW APN followed by the F HFD, F LFD, M LFD, and M HFD mice (Fig. 4A) (P < 0.05). Based on this finding, we designed our subsequent experiments to test the hypothesis that APN increases following estrogen deficiency, which serves as a protective factor against impaired insulin signaling and adipose inflammation exhibited by male mice of similar body composition.
**APN deficiency mitigates HFD-induced body fat accrual in gonadally intact males and females but not in OVX females.** WT and APN KO male and female (both gonadally intact and OVX) mice were placed on a HFD for 16 weeks (n = 19–46). Prior to the initiation of any experiment, in addition to genotyping, we confirmed via western blot that all APN KO mice were APN deficient (Supplementary Fig. 4). When comparing gonadally intact males and females, there was a main effect for APN deficiency to decrease body weight gain, body fat%, visceral fat accumulation, and lean mass (Fig. 4B–D) (P < 0.05). Post-hoc analysis showed that female and male APN KO mice displayed less body weight gain, body fat%, and visceral fat mass, but not lean mass compared to their WT littermate controls (P < 0.05). When comparing male and OVX mice, a main effect of genotype was found for body weight gain, body fat%, visceral fat accumulation and lean mass as APN deficiency decreased all of these outcomes (P < 0.05). A main effect of gonadal status was also found with respect to body fat% and visceral fat with OVX increasing these parameters as well as for lean mass with OVX decreasing this outcome (P < 0.05). With respect to post-hoc analyses, male APN KO mice displayed a lower body weight gain, body fat%, and visceral fat compared to all other groups, whereas OVX WT and OVX APN KO mice displayed an increased body fat%, visceral fat accumulation, and less lean mass than both male groups (P < 0.05).

**APN deficiency enhances insulin sensitivity in males and females, but has no beneficial metabolic effects in OVX females.** Fasting blood glucose and insulin were assessed at 12 and 16 weeks of dietary treatment as well as fasting serum free-fatty acids and plasma triglycerides after 16 weeks of dietary treatment (Supplementary Fig. 5). Among gonadally intact males and females there was a main effect of sex to impact blood glucose levels as male mice displayed higher fasting blood glucose levels after 12 and 16 weeks of dietary treatment compared to female mice (Supplementary Fig. 5A-B) (P < 0.05). Post-hoc analysis showed that male APN KO mice displayed significantly lower fasting blood glucose levels after 12 and 16 weeks of dietary treatment compared to WT littermate controls (P < 0.05). When comparing male and OVX mice, a main effect for gonadal status was found at 12 weeks for fasting blood glucose with OVX mice presenting lower blood glucose concentrations than male mice (P < 0.05). With respect to insulin, when comparing gonadally intact males and females, main effects for both sex and genotype were found after 12 and 16 weeks of dietary treatment with females presenting lower insulin levels than males and APN KO mice presenting lower insulin levels than WT mice (Supplementary Fig. 5C-D) (P < 0.05). Post-hoc analysis showed that male APN KO mice presented lower fasting insulin levels both at 12 and 16 weeks of dietary treatment compared to WT male mice, whereas female APN KO mice only presented lower insulin levels after 16 weeks of dietary treatment compared to female WT mice (P < 0.05). When comparing male and OVX mice with respect to insulin levels, there were significant main effects for genotype (APN KO) and gonadal status (OVX) after 12 and 16 weeks of dietary treatment and an interaction (male APN KO vs. male WT only) after 12 weeks of dietary treatment (Supplementary Fig. 5C-D) (P < 0.05). Regarding free-fatty acid and triglyceride levels, only a main effect of sex was found to
be statistically significant with female mice exhibiting lower levels of these molecules compared to male mice (Supplementary Fig. 5E-F) (P < 0.05). On the other hand, when comparing male and OVX mice, a main effect was found for gonadal status with OVX mice displaying higher values for both lipid molecules relative to male mice (P < 0.05).

In addition to assessing fasting metabolic parameters, we also performed metabolic tests (GTTs and ITTs) after 16 weeks of dietary treatment (Fig. 5). With respect to the GTT, when comparing males and females, a main effect of sex was found to be statistically significant with males presenting impaired glucose tolerance relative to females (Fig. 5A) (P < 0.05). No statistically significant main effects with respect to the GTTs were found between male and OVX mice. Interestingly, however, we analyzed blood insulin concentrations over the course of the GTT and found significant main effects of both sex (females < insulin AUC) and genotype (APN KO < insulin AUC) to impact blood insulin concentrations (Fig. 5B) (P < 0.05). The post-hoc analysis revealed that both male and female APN KO presented significantly lower insulin levels over the course of the GTT than WT mice, suggesting that the APN KO mice exhibit greater insulin sensitivity than their WT littermates given that it took less insulin to elicit the same overall glucose response during the GTT (P < 0.05). When comparing male and OVX mice, significant main effects for gonadal status (OVX mice < insulin AUC) and genotype (APN KO < insulin AUC) were observed. However, the post-hoc analysis revealed no significant difference between WT OVX and APN OVX mice.

With respect to the ITT, APN deficiency was found to be beneficial with respect to insulin sensitivity as a main effect of genotype was evident for all 2-way ANOVA comparisons (Fig. 5C) (P < 0.05). Specifically, post-hoc analysis revealed that male APN KO mice were more insulin sensitive than male WT mice, however, this was not true when comparing female WT and APN KO mice and OVX WT and APN KO mice (P < 0.05). It should be noted, however, that the inability to detect an AUC difference between the female WT and female APN groups may be explained by the fact that both groups of mice presented enhanced insulin sensitivity compared to their male counterparts. The ITT is not a delicate enough test to tease out differences in insulin sensitivity between male and females.

Figure 3. Despite a similar degree of adiposity, HFD estrogen-deficient females exhibit enhanced insulin sensitivity relative to HFD males. After 16 weeks of LFD or HFD, mice (n = 10) were assessed metabolically by examining (A) fasting insulin levels, (B) a glucose tolerance test (GTT), (C) insulin response to the GTT, (D) insulin tolerance test (ITT), and (E) skeletal-muscle-specific insulin-induced AKT activation (n = 4–5). Data is presented as mean ± SE. Bar graphs not sharing a common letter are significantly different from one another (P < 0.05).
highly insulin sensitive mice. Thus, given the fact that the female APN KO mice presented with lower fasting insulin levels as well as lower insulin levels over the course of the GTT with a similar net glucose response, it is suggested that the female APN KO mice present enhanced insulin sensitivity compared to their female WT controls.

APN deficiency limits adipose tissue inflammation in gonadally intact males and females, but not OVX mice. Adipose tissue inflammation was assessed via qRT-PCR and is presented in Fig. 6. In general, adiponectin deficiency reduced inflammatory markers—macrophage markers, in particular—in both gonadally intact male and female mice (Fig. 6A,B) (P < 0.05). Interestingly, however, APN deficiency did not impact adipose tissue inflammation in the OVX mice (Fig. 6C). In order to corroborate the decrease in inflammation we observed at the mRNA level, we performed a western blot for p-JNK in the adipose tissue of male APN KO and WT mice (Fig. 6D). As expected, we found JNK activation to be significantly lower in the male APN KO mice (P < 0.05).

Because APN has been shown to be regulated by PPARγ, a master regular of adipogenesis, we assessed adipogenic markers including, PPARγ and PGC1-α. In the gonadally-intact female mice, PPARγ was found to be increased in APN KO mice relative to WT littermates (Supplementary Fig. 6) (P < 0.05). PPARγ was found to be increased in APN KO mice relative to WT littermates (Supplementary Fig. 6) (P < 0.05).

APN deficiency dramatically reduces hepatic steatosis in male mice. We assessed the degree to which APN deficiency impacted hepatic steatosis (Fig. 7). When comparing between gonadally intact males and females, there was a main effect of genotype, with APN KO mice exhibiting less hepatic steatosis than WT littermates (P < 0.05). The post-hoc assessment showed that only male APN KO mice presented significantly lower hepatic steatosis than WT counterparts.

Figure 4. Estrogen deficiency increases high-molecular-weight (HMW) adiponectin (APN), and APN deletion mitigates HFD-induced body fat accrual in gonadally intact males and females but not in ovariectomized females. After 16 weeks of LFD or HFD, (A) plasma was assessed for HMW APN in WT mice (n = 6–10). A subsequent 16-week HFD experiment was performed utilizing male and female (both intact and OVX) APN deficient mice (M and F APN−/−) and wildtype (WT) littermate controls (n = 19–46). The data is presented as follows, (B) body weight over the course of the study as well as % body weight change from baseline, (C) body fat %, (D) visceral fat accumulation, and (E) lean mass. Bar graphs not sharing a common letter or symbol are significantly different from one another (P < 0.05). ME = Main Effect.
less hepatic lipid accumulation than male WT mice, which was evident histologically (P < 0.05). Similarly, when comparing male and OVX mice, a main effect of genotype was found with APN KO mice exhibiting less hepatic steatosis (P < 0.05). However, no significant difference was found between WT OVX and APN OVX with respect to the degree of hepatic steatosis.

Slight, but non-statistically significant differences in food intake and energy expenditure leading to a net difference in energy balance likely explain the reduced body weight exhibited by male APN KO mice. Although male and female APN KO mice presented a statistically significant difference in body weight gain, and visceral fat mass accumulation compared to their WT littermates, this phenotype was stronger in APN KO males relative to their male WT littermates. Given this more pronounced phenotype, we explored whether differences in food intake could explain these outcomes. Male APN KO (n = 10) and WT (n = 15) mice were singly housed for 16 weeks of dietary treatment (Supplementary Fig. 6). Similar to our initial experiment, we confirmed our previous finding that male APN KO mice do not gain as much body weight as their WT littermate controls (Supplementary Fig. 7A) (P < 0.05). Additionally, we found no difference in food intake over the course of the feeding period (Supplementary Fig. 6B), suggesting that differences in food intake do not explain the dissimilarities in body weight gain. Subsequently, we placed male APN KO and WT mice in high-resolution metabolic cages for a 10-day experiment. We did not find any statistically significant changes with respect to food intake (Fig. 8A), energy expenditure (Fig. 8B), physical activity, or resting energy expenditure between the two groups (Supplementary Table 1). However, when examining total energy balance, we found that the APN KO mice presented a significantly lower net energy balance than WT mice resulting in

Figure 5. Adiponectin deficiency enhances insulin sensitivity in males and females, but has no beneficial metabolic effects in ovariectomized females. After 16 weeks of HFD, mice (n = 19–46) were assessed metabolically by examining (A) GTT, (B) insulin response to the GTT, and (C) ITT. Data is presented as mean ± SE. Bar graphs not sharing a common letter or symbol are significantly different from one another (P < 0.05). ME = Main Effect.
an ≈ 10 kcal difference (i.e. 7% of total energy intake) over the 10-day run between the two groups (Fig. 8C,D) (P < 0.05). This was paired with a lower RER (Supplementary Table 1) and lower resting RER as determined...
during the 30 min of lowest energy expenditure during the light cycle (Fig. 8E,F) (P < 0.05). Over time, this net energy balance deficit is likely responsible for the decreased body weight gain that the APN KO phenotype presents after approximately 12–14 weeks of HFD treatment. This outcome is explained by slight, non-statistical differences in food intake and energy expenditure.

Discussion

It is well established that estrogen deficiency both in humans and animal models increases the susceptibility to obesity and metabolic dysfunction\(^1\). Our data corroborates this as estrogen deficiency (OVX) exacerbated HFD-induced obesity in female mice. However, here we show that despite a higher body fat percentage and a similar degree of hepatic and skeletal muscle lipid accumulation, female estrogen-deficient (OVX) HFD-fed mice exhibit significantly enhanced insulin sensitivity relative to HFD-fed males. Given that we found significant increases in plasma HMW APN in HFD OVX mice and contrary decreases in male HFD mice, we hypothesized that APN may be the key molecular factor regulating the enhanced insulin sensitivity exhibited by the estrogen-deficient females relative to the males. Utilizing APN KO mice we tested this hypothesis and found that APN deficiency limited adiposity gains, mitigated HFD-induced insulin resistance, and minimized adipose tissue inflammation in gonadally intact male and female mice, but not in OVX mice. Thus, APN is not the molecule that protects OVX HFD mice from the same degree of insulin resistance as HFD male mice. Moreover, there is an interaction between gonadal status and adiponectin tone; where basal APN negatively affects insulin action when mice are gonadally intact, but not in the setting of OVX.

From a clinical perspective, the data on APN as a therapeutic agent and the role it plays in metabolic disorders remains controversial and ambiguous. For example, a number of epidemiological studies have found that low circulating levels of APN have been linked to a variety of diseases as reviewed by Ye et al.\(^4\). However, other epidemiological data do not support a causal role of lower circulating APN levels in insulin resistance and T2D\(^5\). Furthermore, large-scale data have shown a positive association between circulating APN levels and mortality rate\(^6\), which has led to the suggestion that there exists an “APN Paradox” in which high levels of APN do not translate to beneficial metabolic outcomes in humans\(^44\). The mechanisms for this paradox are an ongoing field of investigation, but it is believed that there exists a state of “APN resistance”\(^47\). Indeed, APN resistance
has been shown to precede skeletal muscle lipid accumulation and insulin resistance in HFD-fed rats. Thus, our finding that circulating HMW APN is increased in HFD-fed gonadally intact and OVX females relative to LFD-fed females may be interpreted as a compensatory response to APN resistance. However, this same trend was not exhibited in male mice as HFD-fed male mice exhibited significantly less circulating HMW APN than LFD-fed males. Thus, more research is necessary to determine the effect that sex has on HMW APN formation and APN resistance in the setting of obesity.

Much of the molecular mechanisms responsible for APN action are based on basic science research. The vast majority of this research suggests a beneficial metabolic effect of APN action, which was recently highlighted in an elegant paper by Dr. Philipp Scherer’s group showing that APN “preserves metabolic fitness during aging.”

Nonetheless, when examining the literature closely, the discrepancies in the APN basic science literature with respect to APN deletion come to light.
Three different congenital knockout models (we have identified as the Kadowaki, Matsuzawa, and Scherer models) have found APN deletion to induce a phenotype of mild metabolic dysfunction with respect to insulin sensitivity and glucose tolerance. Furthermore, Dr. Scherer's group has recently shown that acute loss of APN elicits a more severe systemic insulin resistant phenotype and hyperlipidemia than the congenital KO model his group developed. Similarly, overexpression of APN as well as its receptors have been shown to provide substantial metabolic benefits. Additionally, Dr. Gary Sweeney's group has published a number of papers shown the metabolic benefits of APN action, particularly in skeletal muscle. On the contrary, in a fourth congenital KO model (identified as the Chan model), APN deletion was found to increase skeletal muscle and hepatic beta oxidation without affecting glucose tolerance or insulin sensitivity. The discrepancy in the Chan congenital KO model relative to the other three congenital models has been hypothesized to be attributed to the mechanism APN genetic disruption was achieved which is thought to lead to a gain-of-function, rather than a loss-of-function phenotype. However, follow-up studies by different investigators utilizing either the Matsuzawa or Scherer models have uncovered phenotypes which differ than those described in the original publications. This suggests that environmental factors, rather than genetic factors, play a role in impacting the APN deficient phenotype. For example, although glucose metabolism was not assessed, utilizing the Matsuzawa model, Dr. Harvey Lodish's group found that APN KO mice weigh less, exhibit significantly less epididymal fat weight, and show dramatically less hepatic steatosis when challenged with a high-fat diet (HFD)—all findings not described in the original publication utilizing this mouse model. Additionally, using the Scherer model it was found that these APN KO mice present reduced body weight and are resistant to HFD-induced obesity—a phenotype also not described in the original publication of this model.

Before initiating this study with the APN KO mouse model, we purposely reached out to Dr. Scherer in order to utilize the APN KO mice his group developed as we were aware of the controversy surrounding the different congenital APN KO models. Thus, in this study we utilized the Scherer APN KO model, generated littermate controls, used a significantly large sample size (n = 19–46), and verified non-detectable levels of plasma APN in all KO animals used. We found that APN deficiency dramatically reduced body weight gain and hepatic steatosis, particularly in males, which supports the finding of Dr. Harvey Lodish's group, and improves insulin sensitivity in gonadally intact males and females. It was our initial thought that perhaps the use of our unique custom diet (40% fat, 47% carbohydrate, and 13% protein of total kcals) was responsible for our findings. It should be noted that we have included a supplementary table (Supplementary Table 2) with this manuscript which details previous studies utilizing APN KO models in the setting of HFD-feeding and details the source and sex of the mouse model, the diet used in the investigation, outcomes with respect to body weight and adiposity changes, as well as any effects on inflammation and metabolism. The notion that our HFD may be responsible for our dissimilar results as other previous publications was based on the fact that the majority of previous studies utilizing congenital APN KO models have used diets consisting of > 45% of total kcals coming from fat, with the most common diet utilized being the 60% HFD from Research Diets. However, when reviewing the literature we found that Dr. Harvey Lodish's group utilized the 60% HFD in their publication—suggesting that our custom diet is not the primary factor regulating this phenotype as they found similar beneficial effects of APN deficiency on adiposity gains and hepatic steatosis.

In order to determine if a potential difference in food intake was responsible for the decreased adiposity displayed by the APN KO mice, we singly housed male WT and APN KO mice for a 16-week period. No differences in food intake were found. Subsequently, we placed male WT and APN KO mice in metabolic cages over a 10-day period after 6 weeks of HFD before there were statistically significant differences in body weight or body composition. Although we did not find and statistically significant differences with respect to energy expenditure or food intake, our instrumentation was sensitive enough to detect a clear difference in net energy balance and body weight between the two genotypes. A subtle decrease in food intake and a matching decrease in energy expenditure resulted in a significantly lower net energy balance in the APN KO mice. Therefore, it is likely that the lower net energy balance exhibited by the male APN KO mice, over time, explains the reduced body weight and decreased adiposity. The molecular mechanisms responsible for this mild, time-dependent phenotype are unclear.

An interesting finding of this investigation is that OVX negatively regulates the beneficial effects of APN deletion. Furthermore, we show that gonadally intact males benefit more from APN deficiency than do gonadally intact females. These findings suggest an interaction between gonadal status and APN tone, which we show impacts metabolic processes. The mechanism(s) responsible for this interaction remain poorly understood. Interestingly, we found PPARγ gene expression to be upregulated as a result of APN deficiency only in the gonadally intact female mice relative to WT littermates. Given the role that PPARγ has in regulating adipogenesis and its interaction with APN, future studies should explore the impact that sex has on the PPARγ-APN crosstalk. We show that APN is not that mechanistic link. We can only surmise that although OVX HFD-females display enhanced insulin sensitivity relative to HFD males despite a similar degree of adiposity and ectopic lipid accumulation. We show that APN is not that mechanistic link. We can only surmise that although OVX HFD-females display enhanced insulin sensitivity relative to HFD males despite a similar degree of adiposity and ectopic lipid accumulation.
tissue is responsible for the dichotomy in insulin sensitivity between these groups\textsuperscript{58,60}. Future studies would need to be designed to examine and test this hypothesis.

In conclusion, we find that APN ablation does not have an effect on obesity development, glucose metabolism, or insulin resistance in O VX females. On the contrary, APN deficiency in gonadally intact mice mitigates obesity development and positively influences insulin sensitivity in a HFD setting, which is likely explained by subtle changes in food intake and energy expenditure leading to a lower net energy balance over time. Whether these results are due to compensatory factors as a result of congenital deletion of APN is unknown. Given the inconsistent findings with respect to APN deficiency in the hands of different investigators paired with the fact that we show that sex as well as gonadal status impact the APN deficient phenotype, future studies are needed to tease out the environmental and physiological (e.g. sex steroids) factors which are responsible for these effects.

Data availability
All data is available upon request to the corresponding author.

Received: 8 June 2022; Accepted: 23 September 2022
Published online: 05 October 2022

References

1. Nuutila, P. et al. Gender and insulin sensitivity in the heart and in skeletal muscles. Studies using positron emission tomography. *Diabetes* **44**, 31–36 (1995).

2. Donahue, R. P., Bean, J. A., Donahue, R. A., Goldberg, R. B. & Prineas, R. J. Insulin response in a triphasic population: Effects of sex, ethnic origin, and body fat. *Miami Community Health Study. Diabetes Care* **20**, 1670–1676 (1997).

3. Lovejoy, J. C., Champagne, C. M., de Jonge, L., Xie, H. & Smith, S. R. Increased visceral fat and decreased energy expenditure during the menopausal transition. *Int. J. Obs. (Lond.)* **32**, 949–958. https://doi.org/10.1038/jo.2008.25 (2008).

4. Wandell, P. E. & Carlsson, A. C. Gender differences and time trends in incidence and prevalence of type 2 diabetes in Sweden—A model explaining the diabetes epidemic worldwide today?. *Diabetes Res. Clin. Pract.* **106**, e90–92. https://doi.org/10.1016/j.diabetes.2014.09.013 (2014).

5. Logue, J. et al. Do men develop type 2 diabetes at lower body mass indices than women?. *Diabetologia* **54**, 3003–3006. https://doi.org/10.1007/s00125-011-2313-3 (2011).

6. Lipscombre, L. L. & Hux, J. E. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: A population-based study. *Lancet* **369**, 750–756. https://doi.org/10.1016/S0140-6736(06)60361-4 (2007).

7. Darabi, H. et al. Adiponectin as a protective factor against the progression toward type 2 diabetes mellitus in postmenopausal women. *Medicine (Baltimore)* **94**, e1347. https://doi.org/10.1097/MD.000000000001347 (2015).

8. Menzaghi, C. & Trischitta, V. The adiponectin paradox for all-cause and cardiovascular mortality. *Diabetes* **67**, 12–22. https://doi.org/10.2337/db17-0016 (2018).

9. Jang, A. Y., Scherer, P. E., Kim, J. Y., Lim, S. & Koh, K. K. Adiponectin and cardiometabolic trait and mortality: where do we go?. *Cardiovasc. Res.* https://doi.org/10.1093/cvr/cvab199 (2021).

10. Li, N. et al. Adiponectin preserves metabolic fitness during aging. *Elife*. https://doi.org/10.7554/eLife.65108 (2021).

11. Chen, M. J. et al. The promoting effect of adiponectin in hepatocellular carcinoma. *J. Surg. Oncol.* **106**, 181–187. https://doi.org/10.1002/jso.23059 (2012).

12. Qiao, L., Kinney, B., Schaack, J. & Shao, J. Adiponectin inhibits lipolysis in mouse adipocytes. *Diabetes* **60**, 1519–1527. https://doi.org/10.2337/db10-1017 (2011).

13. Liu, Q. et al. Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism. *Proc. Natl. Acad. Sci. USA* **109**, 14568–14573. https://doi.org/10.1073/pnas.1211611110 (2012).

14. Ma, K. et al. Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. *J. Biol. Chem.* **277**, 34658–34661. https://doi.org/10.1074/jbc.C200362200 (2002).

15. Combs, T. P. et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. *Diabetes* **52**, 268–276. https://doi.org/10.2337/diabetes.52.2.268 (2003).

16. Leung, K. C. et al. Adiponectin isoform distribution in women—relationship to female sex steroids and insulin sensitivity. *Metabolism* **58**, 239–245 (2009).

17. Kunnari, A. et al. Estrogen replacement therapy decreases plasma adiponectin but not resistin in postmenopausal women. *Metabolism* **57**, 1509–1515 (2008).

18. Enos, R. T. et al. Influence of dietary saturated fat content on adiposity, macrophage behavior, inflammation, and metabolism: Composition matters. *J. Lipid Res.* **54**, 152–163. https://doi.org/10.1194/jlr.M303707 (2013).

19. Enos, R. T. et al. A low dose of dietary quercetin fails to protect against the development of an obese phenotype in mice. *PLoS ONE* **11**, e0167979. https://doi.org/10.1371/journal.pone.0167979 (2016).

20. Bader, I. E. et al. Repeated clodronate-liposome treatment results in neutrophilia and is not effective in limiting obesity-linked metabolic impairments. *Am. J. Physiol. Endocrinol. Metab.* **316**, E358–E372. https://doi.org/10.1152/ajpendo.00438.2018 (2019).

21. Enos, R. T. et al. Lowering the dietary omega-6: Omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model. *Nutr. Res.* **35**, 449–459. https://doi.org/10.1016/j.nutres.2015.04.003 (2015).

22. Enos, R. T., Velazquez, K. T. & Murphy, E. A. Insight into the impact of dietary saturated fat on tissue-specific cellular processes underlying obesity-related diseases. *J. Nutr. Biochem.* **25**, 600–612. https://doi.org/10.1016/j.jnutbio.2014.01.011 (2014).

23. Enos, R. T. et al. High-fat diets rich in saturated fat protect against azoxymethane/dextran sulfate sodium-induced colon cancer. *Am. J. Physiol. Gastrointest. Liver Physiol.* **310**, G906–919. https://doi.org/10.1152/ajpgi.00345.2015 (2016).

24. Velazquez, K. T. et al. miR155 deficiency aggravates high-fat diet-induced adipose tissue fibrosis in male mice. *Physiol. Rep.* **5**, e13412 (2017).

25. Cronford, T. L. et al. Role of MCP-1 on inflammatory processes and metabolic dysfunction following high-fat feedings in the FVB/N strain. *Int. J. Obs. (Lond.)* **40**, 844–851. https://doi.org/10.1038/jio.2015.244 (2016).

26. Aladhami, A. K. et al. Macrophage tumor necrosis factor-alpha deletion does not protect against obesity-associated metabolic dysfunction. *FASEB J* **35**, e21665. https://doi.org/10.1096/fj.202100543R (2021).

27. Virtue, S. & Vidal-Puig, A. G/TIs and ITIs in mice: Simple tests, complex answers. *Nat. Metab.* **3**, 883–886. https://doi.org/10.1038/s42255-021-00414-7 (2021).

28. Schwartz, D. M. & Wolins, N. E. A simple and rapid method to assay triacylglycerol in cells and tissues. *J. Lipid Res.* **48**, 2514–2520. https://doi.org/10.1194/jlr.D700017-JLR200 (2007).

29. Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* **3**, RESEARCH0034 (2002).
30. Carson, J. A., Lee, W. J., McClung, J. & Hand, G. A. Steroid receptor concentration in aged rat hindlimb muscle: Effect of anabolic steroid administration. J. Appl. Physiol. 1995(93), 242–250. https://doi.org/10.1152/japplphysiol.01212.2001 (2002).

31. Bader, J. E. et al. Macrophage depletion using clodronate liposomes decreases tumorigenicity and alters gut microbiota in the AOM/DSS mouse model of colon cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 00229, 02017. https://doi.org/10.1152/ajpgi.00229.2017 (2017).

32. Aldridge, G. M., Podrebarac, D. M., Greenough, W. T. & Weiler, I. J. The use of total protein stains as loading controls: An alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J. Neurosci. Methods 172, 250–254. https://doi.org/10.1016/j.jneumeth.2008.05.003 (2008).

33. Morris, E. M. et al. Difference in housing temperature-induced energy expenditure elicits sex-specific diet-induced metabolic adaptations in mice. Obesity (Silver Spring) 28, 1922–1931. https://doi.org/10.1002/oby.22920 (2020).

34. Mina, A. I.

35. Bader, J. E. et al. Macrophage depletion using clodronate liposomes decreases tumorigenicity and alters gut microbiota in the AOM/DSS mouse model of colon cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 00229, 02017. https://doi.org/10.1152/ajpgi.00229.2017 (2017).

36. Mauvais-Jarvis, F., Clegg, D. J. & Hevener, A. L. The role of estrogens in control of energy balance and glucose homeostasis. Endocr. Rev. 34, 309–338. https://doi.org/10.1210/er.2012-1055 (2013).

37. Monteiro, R., Teixeira, D. & Calhau, C. Estrogen signaling in metabolic inflammation. Mediators Inflamm. 2014, 615917. https://doi.org/10.1155/2014/615917 (2014).

38. Wang, Z. V. & Scherer, P. E. Adiponectin, the past two decades. J. Mol. Cell Biol. 8, 93–100. https://doi.org/10.1093/jmcb/mjw011 (2016).

39. Astapova, O. & Leff, T. Adiponectin and PPARgamma: cooperative and interdependent actions of two key regulators of metabolism. Vitam. Horm. 90, 143–162. https://doi.org/10.1016/B978-0-12-398313-8.00003-3 (2012).

40. Chambers, J. M. & Wingert, R. A. PGC-1alpha in disease: Recent renal insights into a versatile metabolic regulator. Cells. https://doi.org/10.3390/cells9102344 (2020).

41. Riant, E. et al. Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 150, 2109–2117. https://doi.org/10.1210/en.2008-0971 (2009).

42. Ye, R. & Scherer, P. E. Adiponectin, driver or passenger on the road to insulin sensitivity?. Mol. Metab. 2, 133–141. https://doi.org/10.1016/j.molmet.2013.04.001 (2013).

43. Yaghoobt, H. et al. Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 62, 3589–3598. https://doi.org/10.2337/db13-0128 (2013).

44. Kalkman, H. O. An explanation for the adiponectin paradox. Pharmaceuticals (Basel) https://doi.org/10.3390/ph14122166 (2021).

45. Semple, R. K. et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes 56, 1712–1717. https://doi.org/10.2337/db06-1665 (2007).

46. Woodward, L., Akoumianakis, I., & Antoniades, C. Unravelling the adiponectin paradox: Novel roles of adiponectin in the regulation of cardiovascular disease. Br. J. Pharmacol. 174, 4007–4020. https://doi.org/10.1111/bph.13619 (2017).

47. Tahinsky, J. M., Robinson, L. E. & Dyck, D. J. Insulin-sensitizing properties of adiponectin. Biochimie 94, 2131–2136. https://doi.org/10.1016/j.biochi.2012.01.017 (2012).

48. Mullen, K. L. et al. Adiponectin resistance precedes the accumulation of skeletal muscle lipids and insulin resistance in high-fat-fed rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296, R243–251. https://doi.org/10.1152/ajpregu.90774.2009 (2009).

49. Kubota, N. et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 277, 25863–25866. https://doi.org/10.1074/jbc.C200251200 (2002).

50. Maeda, N. et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8, 731–737. https://doi.org/10.1038/nm724 (2002).

51. Nawrocki, A. R. et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 281, 2654–2660. https://doi.org/10.1074/jbc.M505511200 (2006).

52. Xia, J. Y. et al. Acute loss of adipose tissue-derived adiponectin triggers immediate metabolic deterioration in mice. Diabetologia 61, 932–941. https://doi.org/10.1007/s00125-017-4516-8 (2018).

53. Combs, T. P. et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145, 367–383. https://doi.org/10.1210/en.2003-1068 (2004).

54. Holland, W. L. et al. Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis. Mol. Metab. 6, 267–275. https://doi.org/10.1016/j.molmet.2017.01.002 (2017).

55. Liu, Y. & Sweeney, G. Adiponectin action in skeletal muscle. Best Pract. Res. Clin. Endocrinol. Metab. 28, 33–41. https://doi.org/10.1016/j.beem.2013.08.003 (2014).

56. Vu, V., Liu, Y., Sen, S., Xu, A. & Sweeney, G. Delivery of adiponectin gene to skeletal muscle using ultrasound targeted microbubbles improves insulin sensitivity and whole body glucose homeostasis. Am. J. Physiol. Endocrinol. Metab. 304, E168–175. https://doi.org/10.1152/ajpendo.00493.2012 (2013).

57. Krause, M. P. et al. Adiponectin is expressed by skeletal muscle fibers and influences muscle phenotype and function. Am. J. Physiol. Cell Physiol. 295, C203–212. https://doi.org/10.1152/ajpcell.00302.2008 (2008).

58. Liu, Y. et al. Functional significance of skeletal muscle adiponectin production, changes in animal models of obesity and diabetes, and regulation by rosiglitazone treatment. Am. J. Physiol. Endocrinol. Metab. 297, E657–664. https://doi.org/10.1152/ajpendo.00186.2009 (2009).

59. Petersen, M. C. & Shulman, G. I. Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends Pharmacol. Sci. 38, 649–665. https://doi.org/10.1016/j.tips.2017.04.004 (2017).

60. Petersen, M. C. & Shulman, G. I. Mechanisms of insulin action and insulin resistance. Physiol. Rev. 98, 2133–2223. https://doi.org/10.1152/physrev.00063.2017 (2018).

Acknowledgements
We thank Dr. Philipp Scherer (UT-Southwestern) for his kind donation of the APN KO mice.

Author contributions
C.A.U.: validation, formal analysis, data curation, visualization, review and editing of the manuscript, investigation. A.K.A.: data curation, review and editing of the manuscript, supervision. M.C.H.: review and editing of the manuscript, investigation. S.P.: data curation, review and editing of the manuscript, investigation. M.N.: review and editing of the manuscript, supervision. O.P.M.: review and editing of the manuscript, formal analysis, supervision. E.A.M.: supervision, review and editing of the manuscript, resources. K.T.Y.: resources, investigation, data curation, review and editing of the manuscript. R.T.E.: conceptualization, data curation.
formal analysis, funding acquisition, supervision, project administration, visualization, writing of original draft, resources, investigation, validation, methodology.

**Funding**
This work was supported by grants K01-AT010348 (NIH-NCCIH) and the University of South Carolina Advanced Support for Innovative Research Excellence (ASPIRE) to RTE. KTV is supported by R00-AT009206 (NIH-NCCIH). OPM was supported by U24-DK059637 and P30-DK20593. The funding sources had no role in the collection, analysis and interpretation of the data, writing of the report, or decision to submit the article for publication.

**Competing interests**
The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-21228-x.

**Correspondence** and requests for materials should be addressed to R.T.E.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022